{"protocolSection":{"identificationModule":{"nctId":"NCT02453282","orgStudyIdInfo":{"id":"D419AC00001"},"secondaryIdInfos":[{"id":"2015-001279-39","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","officialTitle":"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).","acronym":"MYSTIC"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-07-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-10-04","type":"ACTUAL"},"completionDateStruct":{"date":"2025-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-05-20","studyFirstSubmitQcDate":"2015-05-22","studyFirstPostDateStruct":{"date":"2015-05-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-10-04","resultsFirstSubmitQcDate":"2019-11-19","resultsFirstPostDateStruct":{"date":"2019-11-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-12","lastUpdatePostDateStruct":{"date":"2025-09-16","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC","detailedDescription":"Patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy, or Standard of Care (SoC) therapy."},"conditionsModule":{"conditions":["Non-Small-Cell Lung Carcinoma NSCLC"],"keywords":["NSCLC, PD-L1, MEDI4736, Tremelimumab, PFS, OS"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1118,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Monotherapy","type":"EXPERIMENTAL","description":"PD-L1 monoclonal Antibody monotherapy.","interventionNames":["Biological: MEDI4736 (Durvalumab)"]},{"label":"Combination Therapy","type":"EXPERIMENTAL","description":"PD-L1+Tremelimumab combination therapy","interventionNames":["Biological: MEDI4736 (Durvalumab)+Tremelimumab","Biological: Tremelimumab"]},{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","description":"Standard of Care chemotherapy treatment","interventionNames":["Drug: Paclitaxel + Carboplatin","Drug: Gemcitabine + Cisplatin","Drug: Gemcitabine + Carboplatin","Drug: Pemetrexed + Cisplatin","Drug: Pemetrexed + Carboplatin"]}],"interventions":[{"type":"BIOLOGICAL","name":"MEDI4736 (Durvalumab)","armGroupLabels":["Monotherapy"]},{"type":"BIOLOGICAL","name":"MEDI4736 (Durvalumab)+Tremelimumab","armGroupLabels":["Combination Therapy"]},{"type":"DRUG","name":"Paclitaxel + Carboplatin","description":"Chemotherapy Agents","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Gemcitabine + Cisplatin","description":"Chemotherapy Agents","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Gemcitabine + Carboplatin","description":"Chemotherapy Agents","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Pemetrexed + Cisplatin","description":"Chemotherapy Agents","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"DRUG","name":"Pemetrexed + Carboplatin","description":"Chemotherapy Agents","armGroupLabels":["Standard of Care"],"otherNames":["Platinum based Standard of Care Chemotherapy"]},{"type":"BIOLOGICAL","name":"Tremelimumab","armGroupLabels":["Combination Therapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy","description":"The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."}],"secondaryOutcomes":[{"measure":"OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","timeFrame":"From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"OS; PD-L1 (TC >=1%) Analysis Set Population","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","timeFrame":"From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"OS; FAS Population","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","timeFrame":"From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","description":"The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"PFS; PD-L1 (TC >=1%) Analysis Set Population","description":"The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"PFS; FAS Population","description":"The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population","description":"The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"ORR; PD-L1 (TC >=1%) Analysis Set Population","description":"The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"ORR; FAS Population","description":"The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population","description":"The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"DoR; PD-L1 (TC >=1%) Analysis Set Population","description":"The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"DoR; FAS Population","description":"The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years)."},{"measure":"Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population","description":"The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months."},{"measure":"Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population","description":"The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months."},{"measure":"Percentage of Participants APF12; FAS Population","description":"The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months."},{"measure":"Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years)."},{"measure":"PFS2; PD-L1 (TC >=1%) Analysis Set Population","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years)."},{"measure":"PFS2; FAS Population","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years)."},{"measure":"Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months","description":"Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of \\>=10.","timeFrame":"At baseline then every 4 weeks for the first 8 weeks relative to the date of randomization, then every 8 weeks until second progression/death, whichever comes first. Assessed up to 12 months."},{"measure":"Serum Concentrations of Durvalumab","description":"Blood samples were collected to determine the serum concentration of durvalumab.","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, and at follow-up Month 3."},{"measure":"Serum Concentrations of Tremelimumab","description":"Blood samples were collected to determine the serum concentration of tremelimumab.","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3."},{"measure":"Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab","description":"Blood samples were collected to determine the Cmax\\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.","timeFrame":"Within 1 hour after end of infusion on infusion day at Week 12."},{"measure":"Cmax_ss of Tremelimumab","description":"Blood samples were collected to determine the Cmax\\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.","timeFrame":"Within 1 hour after end of infusion on infusion day at Week 12."},{"measure":"Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab","description":"Blood samples were collected to determine the Ctrough\\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.","timeFrame":"Pre-dose at Week 12."},{"measure":"Ctrough_ss of Tremelimumab","description":"Blood samples were collected to determine the Ctrough\\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.","timeFrame":"Pre-dose at Week 12."},{"measure":"Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab","description":"Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","timeFrame":"At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment."},{"measure":"Number of Participants With ADA Response to Tremelimumab","description":"Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","timeFrame":"At Weeks 0 and 12; 3 and 6 months after last dose of study treatment."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nFor inclusion in the study, patients should fulfill the following criteria:\n\n* Aged at least 18 years\n* Documented evidence of Stage IV NSCLC\n* No sensitizing EGFR mutation or ALK rearrangement\n* No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC\n* World Health Organization (WHO) Performance Status of 0 or 1\n\nExclusion Criteria:\n\nPatients should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant\n2. Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)\n3. Prior exposure to Immunomodulatory therapy (IMT), including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines\n4. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\]","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Stuart McIntosh, MD","affiliation":"AstraZeneca, Alderley Park, Cheshire, UK","role":"STUDY_DIRECTOR"},{"name":"Naiyer Rizvi, MD","affiliation":"Columbia University Medical Center, New York, NY, USA","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Research Site","city":"Scottsdale","state":"Arizona","zip":"85259","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Research Site","city":"Tucson","state":"Arizona","zip":"85715","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Research Site","city":"Yuma","state":"Arizona","zip":"85364","country":"United States","geoPoint":{"lat":32.72532,"lon":-114.6244}},{"facility":"Research Site","city":"Bakersfield","state":"California","zip":"93309","country":"United States","geoPoint":{"lat":35.37329,"lon":-119.01871}},{"facility":"Research Site","city":"Fullerton","state":"California","zip":"92835","country":"United States","geoPoint":{"lat":33.87029,"lon":-117.92534}},{"facility":"Research Site","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Research Site","city":"Los Angeles","state":"California","zip":"90024","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"Los Angeles","state":"California","zip":"90073","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"Redondo Beach","state":"California","zip":"90277","country":"United States","geoPoint":{"lat":33.84918,"lon":-118.38841}},{"facility":"Research Site","city":"Sacramento","state":"California","zip":"95817","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Research Site","city":"San Luis Obispo","state":"California","zip":"93401","country":"United States","geoPoint":{"lat":35.28275,"lon":-120.65962}},{"facility":"Research Site","city":"Santa Maria","state":"California","zip":"93454","country":"United States","geoPoint":{"lat":34.95303,"lon":-120.43572}},{"facility":"Research Site","city":"West Hollywood","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.09001,"lon":-118.36174}},{"facility":"Research Site","city":"New Haven","state":"Connecticut","zip":"06519","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Research Site","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Research Site","city":"Pembroke Pines","state":"Florida","zip":"33028","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"Research Site","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Research Site","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"Research Site","city":"Honolulu","state":"Hawaii","zip":"96819","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Research Site","city":"Baltimore","state":"Maryland","zip":"21231","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Research Site","city":"Minneapolis","state":"Minnesota","zip":"55435","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Research Site","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Research Site","city":"Omaha","state":"Nebraska","zip":"68198","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Research Site","city":"Summit","state":"New Jersey","zip":"07901","country":"United States","geoPoint":{"lat":40.71562,"lon":-74.36468}},{"facility":"Research Site","city":"Mineola","state":"New York","zip":"11501","country":"United States","geoPoint":{"lat":40.74927,"lon":-73.64068}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"Charlotte","state":"North Carolina","zip":"28204","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Research Site","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Research Site","city":"North Charleston","state":"South Carolina","zip":"29406","country":"United States","geoPoint":{"lat":32.85462,"lon":-79.97481}},{"facility":"Research Site","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Research Site","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Research Site","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Research Site","city":"Madison","state":"Wisconsin","zip":"53705","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"Research Site","city":"Box Hill","zip":"3128","country":"Australia","geoPoint":{"lat":-37.81887,"lon":145.12545}},{"facility":"Research Site","city":"Gosford","zip":"2250","country":"Australia","geoPoint":{"lat":-33.4244,"lon":151.34399}},{"facility":"Research Site","city":"Kogarah","zip":"2217","country":"Australia","geoPoint":{"lat":-33.9681,"lon":151.13564}},{"facility":"Research Site","city":"Melbourne","zip":"3000","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Research Site","city":"Port Macquarie","zip":"2444","country":"Australia","geoPoint":{"lat":-31.43084,"lon":152.90894}},{"facility":"Research Site","city":"Southport","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Research Site","city":"St Leonards","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"facility":"Research Site","city":"Brussels","zip":"1090","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Research Site","city":"Charleroi","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"Research Site","city":"Duffel","zip":"2570","country":"Belgium","geoPoint":{"lat":51.09554,"lon":4.50903}},{"facility":"Research Site","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"Research Site","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Research Site","city":"Greater Sudbury","state":"Ontario","zip":"P3E 5J1","country":"Canada","geoPoint":{"lat":46.49,"lon":-80.99001}},{"facility":"Research Site","city":"Kingston","state":"Ontario","zip":"K7L 2V7","country":"Canada","geoPoint":{"lat":44.22976,"lon":-76.48098}},{"facility":"Research Site","city":"Newmarket","state":"Ontario","zip":"L3Y 2P9","country":"Canada","geoPoint":{"lat":44.05011,"lon":-79.46631}},{"facility":"Research Site","city":"Oshawa","state":"Ontario","zip":"L1G 2B9","country":"Canada","geoPoint":{"lat":43.90012,"lon":-78.84957}},{"facility":"Research Site","city":"Sault Ste. Marie","state":"Ontario","zip":"P6A 0A8","country":"Canada","geoPoint":{"lat":46.51677,"lon":-84.33325}},{"facility":"Research Site","city":"St. Catharines","state":"Ontario","zip":"L2S 0A9","country":"Canada","geoPoint":{"lat":43.17126,"lon":-79.24267}},{"facility":"Research Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Research Site","city":"Regina","state":"Saskatchewan","zip":"S4T 7T1","country":"Canada","geoPoint":{"lat":50.45008,"lon":-104.6178}},{"facility":"Research Site","city":"Saskatoon","state":"Saskatchewan","zip":"S7N 4H4","country":"Canada","geoPoint":{"lat":52.13238,"lon":-106.66892}},{"facility":"Research Site","city":"Bordeaux","zip":"33000","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Research Site","city":"Brest","zip":"29609","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Research Site","city":"Créteil","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Research Site","city":"Lille","zip":"59000","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Research Site","city":"Lyon","zip":"69373","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Research Site","city":"Marseille","zip":"13915","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Research Site","city":"Aachen","zip":"52074","country":"Germany","geoPoint":{"lat":50.77664,"lon":6.08342}},{"facility":"Research Site","city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"facility":"Research Site","city":"Berlin","zip":"10967","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Research Site","city":"Berlin","zip":"12351","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Research Site","city":"Freiburg im Breisgau","zip":"79106","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"facility":"Research Site","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Research Site","city":"Hamburg","zip":"20251","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Research Site","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Research Site","city":"Hemer","zip":"58675","country":"Germany","geoPoint":{"lat":51.38707,"lon":7.77019}},{"facility":"Research Site","city":"Homburg/Saar","zip":"66421","country":"Germany"},{"facility":"Research Site","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"Research Site","city":"Löwenstein","zip":"74245","country":"Germany","geoPoint":{"lat":49.09558,"lon":9.38}},{"facility":"Research Site","city":"Lübeck","zip":"23538","country":"Germany","geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"Research Site","city":"Mainz","zip":"55131","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Research Site","city":"Münster","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Research Site","city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"Research Site","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Research Site","city":"Velbert","zip":"42551","country":"Germany","geoPoint":{"lat":51.33537,"lon":7.04348}},{"facility":"Research Site","city":"Würzburg","zip":"97080","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"Research Site","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Deszk","zip":"6772","country":"Hungary","geoPoint":{"lat":46.21802,"lon":20.24322}},{"facility":"Research Site","city":"Edelény","zip":"3780","country":"Hungary","geoPoint":{"lat":48.3,"lon":20.73333}},{"facility":"Research Site","city":"Kaposvár","zip":"7400","country":"Hungary","geoPoint":{"lat":46.36667,"lon":17.8}},{"facility":"Research Site","city":"Kecskemét","zip":"6000","country":"Hungary","geoPoint":{"lat":46.90618,"lon":19.69128}},{"facility":"Research Site","city":"Miskolc","zip":"3529","country":"Hungary","geoPoint":{"lat":48.10327,"lon":20.77806}},{"facility":"Research Site","city":"Nyíregyháza","zip":"4400","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Research Site","city":"Pécs","zip":"7624","country":"Hungary","geoPoint":{"lat":46.07617,"lon":18.22814}},{"facility":"Research Site","city":"Székesfehérvár","zip":"8000","country":"Hungary","geoPoint":{"lat":47.18995,"lon":18.41034}},{"facility":"Research Site","city":"Genova","zip":"16100","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Research Site","city":"Meldola","zip":"47014","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"Research Site","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Milan","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Milan","zip":"20141","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"San Giovanni Rotondo","zip":"71013","country":"Italy","geoPoint":{"lat":41.70643,"lon":15.7277}},{"facility":"Research Site","city":"Siena","zip":"53100","country":"Italy","geoPoint":{"lat":43.31822,"lon":11.33064}},{"facility":"Research Site","city":"Fukushima","zip":"960-1295","country":"Japan","geoPoint":{"lat":37.75,"lon":140.46667}},{"facility":"Research Site","city":"Himeji-shi","zip":"670-8520","country":"Japan"},{"facility":"Research Site","city":"Hirakata-shi","zip":"573-1191","country":"Japan"},{"facility":"Research Site","city":"Hirosaki-shi","zip":"036-8545","country":"Japan"},{"facility":"Research Site","city":"Iizuka-shi","zip":"820-8505","country":"Japan"},{"facility":"Research Site","city":"Iwakuni-shi","zip":"740-8510","country":"Japan"},{"facility":"Research Site","city":"Izumi-shi","zip":"594-0073","country":"Japan"},{"facility":"Research Site","city":"Kanazawa","zip":"920-8641","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Research Site","city":"Kishiwada-shi","zip":"596-8501","country":"Japan"},{"facility":"Research Site","city":"Kobe","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Research Site","city":"Koga-shi","zip":"811-3195","country":"Japan"},{"facility":"Research Site","city":"Kyoto","zip":"607-8062","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Research Site","city":"Kyoto","zip":"615-8256","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Research Site","city":"Mitaka-shi","zip":"181-8611","country":"Japan"},{"facility":"Research Site","city":"Nagaoka-shi","zip":"940-2085","country":"Japan"},{"facility":"Research Site","city":"Nagoya","zip":"460-0001","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Research Site","city":"Nagoya","zip":"466-8560","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Research Site","city":"Okayama","zip":"700-8607","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Research Site","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Research Site","city":"Osaka","zip":"543-0035","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Research Site","city":"Saga","zip":"840-8571","country":"Japan","geoPoint":{"lat":33.23333,"lon":130.3}},{"facility":"Research Site","city":"Saitama-shi","zip":"336-8522","country":"Japan"},{"facility":"Research Site","city":"Sakaishi","zip":"591-8555","country":"Japan","geoPoint":{"lat":33.41239,"lon":132.71218}},{"facility":"Research Site","city":"Sayama","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.51685,"lon":135.56298}},{"facility":"Research Site","city":"Sendai","zip":"980-0873","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Research Site","city":"Shinjuku-ku","zip":"162-8655","country":"Japan"},{"facility":"Research Site","city":"Tokushima","zip":"770-8503","country":"Japan","geoPoint":{"lat":34.06667,"lon":134.56667}},{"facility":"Research Site","city":"Ube-shi","zip":"755-0241","country":"Japan"},{"facility":"Research Site","city":"Yokohama","zip":"236-0024","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Research Site","city":"Yokohama","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Research Site","city":"Yokosuka-shi","zip":"238-8558","country":"Japan"},{"facility":"Research Site","city":"'s-Hertogenbosch","zip":"5223 GZ","country":"Netherlands","geoPoint":{"lat":51.69917,"lon":5.30417}},{"facility":"Research Site","city":"Amsterdam","zip":"1066 CX","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Research Site","city":"Arnhem","zip":"6815 AD","country":"Netherlands","geoPoint":{"lat":51.98,"lon":5.91111}},{"facility":"Research Site","city":"Breda","zip":"4818 CK","country":"Netherlands","geoPoint":{"lat":51.58656,"lon":4.77596}},{"facility":"Research Site","city":"Groningen","zip":"9713 GZ","country":"Netherlands","geoPoint":{"lat":53.21917,"lon":6.56667}},{"facility":"Research Site","city":"Maastricht","zip":"6202 AZ","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"facility":"Research Site","city":"Rotterdam","zip":"3015 GD","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Research Site","city":"Moscow","zip":"105229","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Moscow","zip":"111123","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Moscow","zip":"125315","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Moscow","zip":"143423","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Obninsk","zip":"249036","country":"Russia","geoPoint":{"lat":55.10993,"lon":36.61238}},{"facility":"Research Site","city":"Omsk","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"Research Site","city":"Saint Petersburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Busan","zip":"47392","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Research Site","city":"Changwon-si","zip":"51353","country":"South Korea"},{"facility":"Research Site","city":"Cheongju-si","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Research Site","city":"Daegu","zip":"42415","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Research Site","city":"Daegu","zip":"42601","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Research Site","city":"Daejeon","zip":"35015","country":"South Korea","geoPoint":{"lat":36.34913,"lon":127.38493}},{"facility":"Research Site","city":"Goyang-si","zip":"10408","country":"South Korea","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"Research Site","city":"Incheon","zip":"21565","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Research Site","city":"Jinju","zip":"660-702","country":"South Korea","geoPoint":{"lat":35.19278,"lon":128.08472}},{"facility":"Research Site","city":"Seongnam-si","zip":"13620","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Research Site","city":"Seongnam-si","zip":"463-712","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Research Site","city":"Seoul","zip":"03181","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"134-791","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"156-707","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Suwon","zip":"16499","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Research Site","city":"Ulsan","zip":"44033","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}},{"facility":"Research Site","city":"A Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Research Site","city":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Research Site","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Research Site","city":"Jaén","zip":"23007","country":"Spain","geoPoint":{"lat":37.76922,"lon":-3.79028}},{"facility":"Research Site","city":"León","zip":"24071","country":"Spain","geoPoint":{"lat":42.60003,"lon":-5.57032}},{"facility":"Research Site","city":"Madrid","zip":"28005","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Majadahonda","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"Research Site","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Research Site","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Research Site","city":"Bellinzona","zip":"CH-6500","country":"Switzerland","geoPoint":{"lat":46.19278,"lon":9.01703}},{"facility":"Research Site","city":"Lausanne","zip":"1011","country":"Switzerland","geoPoint":{"lat":46.516,"lon":6.63282}},{"facility":"Research Site","city":"Kaohsiung City","zip":"82445","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Research Site","city":"Kaohsiung City","zip":"83301","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Research Site","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Research Site","city":"Tainan","zip":"70403","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Research Site","city":"Taipei","zip":"112","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Taipei","zip":"235","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Taoyuan District","zip":"333","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}},{"facility":"Research Site","city":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Research Site","city":"Chiang Mai","zip":"50200","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"facility":"Research Site","city":"Hat Yai","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Research Site","city":"Khon Kaen","zip":"40002","country":"Thailand","geoPoint":{"lat":16.44671,"lon":102.833}},{"facility":"Research Site","city":"Hanoi","zip":"100000","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"Research Site","city":"Hanoi","zip":"10000","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"Research Site","city":"Ho Chi Minh City","zip":"700000","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}},{"facility":"Research Site","city":"Ho Chi Minh City","zip":"70000","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}}]},"referencesModule":{"references":[{"pmid":"33775558","type":"DERIVED","citation":"Garon EB, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Robinet G, Le Moulec S, Natale R, Schneider J, Shepherd FA, Garassino MC, Geater SL, Szekely ZP, Van Ngoc T, Liu F, Scheuring U, Patel N, Peters S, Rizvi NA. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021 Jul;22(4):301-312.e8. doi: 10.1016/j.cllc.2021.02.010. Epub 2021 Feb 19."},{"pmid":"32271377","type":"DERIVED","citation":"Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237."}],"seeAlsoLinks":[{"label":"Related Info","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419AC00001&amp;attachmentIdentifier=44a72f97-af1b-4e4c-8b0e-d65a6cc9cc88&amp;fileName=D419AC00001_Statistical_Analysis_Plan_Redacted.pdf&amp;versionIdentifier="},{"label":"Related Info","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D419AC00001&amp;attachmentIdentifier=cbfa257d-1cad-4287-aa97-aaad910d92df&amp;fileName=D419AC00001_Version_8.0_CSP_Redacted.pdf&amp;versionIdentifier="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 1118 participants were randomized in a 1:1:1 ratio in stratified manner as per programmed cell death ligand 1 (PD-L1) tumor expression status (PD-L1 \\[tumor cell (TC) \\>=25%\\] versus (Vs) PD-L1 \\[TC \\<25%\\]) and histology (squamous Vs non-squamous) to receive durvalumab alone, durvalumab + tremelimumab, or standard of care (SoC) chemotherapy.","recruitmentDetails":"A total of 194 centers across 17 countries in Asia, Australia, Europe and North America randomized adults with epidermal growth factor receptor and anaplastic lymphoma kinase wild-type advanced or metastatic non-small cell lung cancer in this study. First participant was randomized on 14 August 2015 and final data cut-off date was 04 October 2018.","groups":[{"id":"FG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 milligram per kilogram (mg/kg) intravenous (IV) infusion every 4 weeks (Q4W) until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"FG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"FG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/square meter (m\\^2) and carboplatin area under the plasma drug concentration-time curve (AUC) 5 or 6 mg\\*minute per milliliter (mg\\*min/mL).\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"374"},{"groupId":"FG001","numSubjects":"372"},{"groupId":"FG002","numSubjects":"372"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"369"},{"groupId":"FG001","numSubjects":"371"},{"groupId":"FG002","numSubjects":"352"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"374"},{"groupId":"FG001","numSubjects":"372"},{"groupId":"FG002","numSubjects":"372"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"275"},{"groupId":"FG001","numSubjects":"277"},{"groupId":"FG002","numSubjects":"296"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"Participants ongoing at data cut-off","reasons":[{"groupId":"FG000","numSubjects":"85"},{"groupId":"FG001","numSubjects":"84"},{"groupId":"FG002","numSubjects":"62"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.","groups":[{"id":"BG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"BG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"BG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"374"},{"groupId":"BG001","value":"372"},{"groupId":"BG002","value":"372"},{"groupId":"BG003","value":"1118"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.2","spread":"10.30"},{"groupId":"BG001","value":"64.3","spread":"9.52"},{"groupId":"BG002","value":"63.6","spread":"9.36"},{"groupId":"BG003","value":"63.7","spread":"9.74"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"122"},{"groupId":"BG003","value":"346"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"256"},{"groupId":"BG001","value":"266"},{"groupId":"BG002","value":"250"},{"groupId":"BG003","value":"772"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"34"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"359"},{"groupId":"BG001","value":"358"},{"groupId":"BG002","value":"366"},{"groupId":"BG003","value":"1083"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"243"},{"groupId":"BG001","value":"249"},{"groupId":"BG002","value":"243"},{"groupId":"BG003","value":"735"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"10"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"120"},{"groupId":"BG003","value":"363"}]},{"title":"Native Hawaiian or other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"}]},{"title":"Missing","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by Ventana PD-L1 (SP263) assay (ie, \\>=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab monotherapy Vs SoC and durvalumab + tremelimumab Vs SoC reporting groups were analysed for primary outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","lowerLimit":"12.2","upperLimit":"20.8"},{"groupId":"OG001","value":"11.9","lowerLimit":"9.0","upperLimit":"17.7"},{"groupId":"OG002","value":"12.9","lowerLimit":"10.5","upperLimit":"15.0"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.036","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.76","ciPctValue":"97.54","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.564","ciUpperLimit":"1.019","estimateComment":"The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.202","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.85","ciPctValue":"98.77","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.611","ciUpperLimit":"1.173","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"PRIMARY","title":"Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy","description":"The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs SoC chemotherapy reporting groups were analysed for the primary outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"2.8","upperLimit":"5.0"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.6","upperLimit":"5.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.705","pValueComment":"The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.05","ciPctValue":"99.5","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.722","ciUpperLimit":"1.534","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs durvalumab monotherapy reporting groups were analysed for the secondary outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","lowerLimit":"12.2","upperLimit":"20.8"},{"groupId":"OG001","value":"11.9","lowerLimit":"9.0","upperLimit":"17.7"},{"groupId":"OG002","value":"12.9","lowerLimit":"10.5","upperLimit":"15.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.523","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.836","ciUpperLimit":"1.421","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"OS; PD-L1 (TC >=1%) Analysis Set Population","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 (TC \\>=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC \\>=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=1% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"296"},{"groupId":"OG002","value":"289"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","lowerLimit":"10.5","upperLimit":"17.7"},{"groupId":"OG001","value":"10.9","lowerLimit":"9.1","upperLimit":"13.5"},{"groupId":"OG002","value":"12.3","lowerLimit":"10.6","upperLimit":"14.6"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.194","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.725","ciUpperLimit":"1.067","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.952","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.834","ciUpperLimit":"1.213","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.218","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.931","ciUpperLimit":"1.371","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"OS; FAS Population","description":"The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants analyzed on an ITT basis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"372"},{"groupId":"OG002","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","lowerLimit":"10.1","upperLimit":"14.9"},{"groupId":"OG001","value":"11.2","lowerLimit":"9.5","upperLimit":"12.9"},{"groupId":"OG002","value":"11.8","lowerLimit":"10.5","upperLimit":"13.3"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.602","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.812","ciUpperLimit":"1.128","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.430","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.794","ciUpperLimit":"1.103","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.802","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.828","ciUpperLimit":"1.157","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","description":"The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by Ventana PD-L1 (SP263) assay (ie, \\>=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs durvalumab and durvalumab Vs SoC reporting groups were analysed for secondary outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"3.1","upperLimit":"6.3"},{"groupId":"OG001","value":"3.9","lowerLimit":"2.8","upperLimit":"5.0"},{"groupId":"OG002","value":"5.4","lowerLimit":"4.6","upperLimit":"5.8"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.324","pValueComment":"The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.667","ciUpperLimit":"1.143","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.207","pValueComment":"The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.18","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.911","ciUpperLimit":"1.541","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"PFS; PD-L1 (TC >=1%) Analysis Set Population","description":"The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 (TC \\>=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC \\>=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=1% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"296"},{"groupId":"OG002","value":"289"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"2.8","upperLimit":"4.2"},{"groupId":"OG001","value":"2.8","lowerLimit":"2.5","upperLimit":"3.4"},{"groupId":"OG002","value":"5.5","lowerLimit":"4.9","upperLimit":"5.7"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.383","pValueComment":"The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.894","ciUpperLimit":"1.339","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.001","pValueComment":"The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.136","ciUpperLimit":"1.678","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.138","pValueComment":"The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.954","ciUpperLimit":"1.403","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"PFS; FAS Population","description":"The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants analyzed on an ITT basis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"372"},{"groupId":"OG002","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"2.6","upperLimit":"3.1"},{"groupId":"OG001","value":"2.9","lowerLimit":"2.6","upperLimit":"3.4"},{"groupId":"OG002","value":"5.4","lowerLimit":"4.8","upperLimit":"5.6"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.015","pValueComment":"The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.24","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.043","ciUpperLimit":"1.475","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.010","pValueComment":"The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.054","ciUpperLimit":"1.485","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.984","pValueComment":"The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.845","ciUpperLimit":"1.179","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population","description":"The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=25% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6"},{"groupId":"OG001","value":"34.4"},{"groupId":"OG002","value":"37.7"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.698","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.582","ciUpperLimit":"1.437","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.534","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.549","ciUpperLimit":"1.363","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."},{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.820","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.601","ciUpperLimit":"1.496","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood."}]},{"type":"SECONDARY","title":"ORR; PD-L1 (TC >=1%) Analysis Set Population","description":"The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","populationDescription":"The PD-L1 (TC \\>=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC \\>=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=1% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"296"},{"groupId":"OG002","value":"289"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5"},{"groupId":"OG001","value":"25.3"},{"groupId":"OG002","value":"33.6"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.050","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.480","ciUpperLimit":"1.000","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (\\>=25% Vs \\<25%), with 95% CI calculated by profile likelihood."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.029","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.464","ciUpperLimit":"0.959","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (\\>=25% Vs \\<25%), with 95% CI calculated by profile likelihood."},{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.887","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.661","ciUpperLimit":"1.430","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (\\>=25% Vs \\<25%), with 95% CI calculated by profile likelihood."}]},{"type":"SECONDARY","title":"ORR; FAS Population","description":"The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","populationDescription":"The FAS included all randomized participants analyzed on an ITT basis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"372"},{"groupId":"OG002","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"24.7"},{"groupId":"OG002","value":"30.1"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.012","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.65","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.462","ciUpperLimit":"0.908","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (\\>=25% Vs \\<25%), with 95% CI calculated by profile likelihood."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.093","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.543","ciUpperLimit":"1.048","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous) and PD-L1 status (\\>=25% Vs \\<25%), with 95% CI calculated by profile likelihood."},{"groupIds":["OG000","OG001"],"groupDescription":"Durvalumab + Tremelimumab Vs Durvalumab Monotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.406","pValueComment":"P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.818","ciUpperLimit":"1.647","estimateComment":"The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous) and PD-L1 status (\\>=25% Vs \\<25%), with 95% CI calculated by profile likelihood."}]},{"type":"SECONDARY","title":"Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population","description":"The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by the Ventana PD-L1 (SP263) assay (ie,\\>=25% TC expressing PD-L1 on the membrane). DoR is only analyzed for those participants with a response (including unconfirmed responses).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"4.9","upperLimit":"NA","comment":"NA = Not reached."},{"groupId":"OG001","value":"NA","lowerLimit":"4.2","upperLimit":"NA","comment":"NA = Not reached."},{"groupId":"OG002","value":"4.4","lowerLimit":"2.9","upperLimit":"7.2"}]}]}]},{"type":"SECONDARY","title":"DoR; PD-L1 (TC >=1%) Analysis Set Population","description":"The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","populationDescription":"The PD-L1 (TC \\>=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC \\>=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=1% TC expressing PD-L1 on the membrane). DoR is only analyzed for those participants with a response (including unconfirmed responses).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"296"},{"groupId":"OG002","value":"289"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"5.5","upperLimit":"NA","comment":"NA = Not reached."},{"groupId":"OG001","value":"NA","lowerLimit":"5.6","upperLimit":"NA","comment":"NA = Not reached."},{"groupId":"OG002","value":"4.4","lowerLimit":"2.8","upperLimit":"8.4"}]}]}]},{"type":"SECONDARY","title":"DoR; FAS Population","description":"The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \\<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).","populationDescription":"The FAS included all randomized participants analyzed on an ITT basis. DoR is only analyzed for those participants with a response (including unconfirmed responses).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"372"},{"groupId":"OG002","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"5.5","upperLimit":"NA","comment":"NA = Not reached."},{"groupId":"OG001","value":"NA","lowerLimit":"4.7","upperLimit":"NA","comment":"NA = Not reached."},{"groupId":"OG002","value":"4.3","lowerLimit":"2.8","upperLimit":"8.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population","description":"The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=25% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months.","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","lowerLimit":"24.8","upperLimit":"39.9"},{"groupId":"OG001","value":"25.8","lowerLimit":"18.9","upperLimit":"33.1"},{"groupId":"OG002","value":"14.3","lowerLimit":"8.4","upperLimit":"21.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population","description":"The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.","populationDescription":"The PD-L1 (TC \\>=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC \\>=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=1% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months.","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"296"},{"groupId":"OG002","value":"289"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","lowerLimit":"21.6","upperLimit":"32.6"},{"groupId":"OG001","value":"20.4","lowerLimit":"15.7","upperLimit":"25.5"},{"groupId":"OG002","value":"14.9","lowerLimit":"10.2","upperLimit":"20.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants APF12; FAS Population","description":"The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants analyzed on an ITT basis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to 12 months.","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"372"},{"groupId":"OG002","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"18.1","upperLimit":"27.1"},{"groupId":"OG001","value":"19.8","lowerLimit":"15.6","upperLimit":"24.4"},{"groupId":"OG002","value":"13.8","lowerLimit":"9.7","upperLimit":"18.6"}]}]}]},{"type":"SECONDARY","title":"Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=25% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"9.4","upperLimit":"16.1"},{"groupId":"OG001","value":"10.9","lowerLimit":"7.9","upperLimit":"14.1"},{"groupId":"OG002","value":"10.4","lowerLimit":"9.0","upperLimit":"12.5"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.030","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.597","ciUpperLimit":"0.975","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.045","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.606","ciUpperLimit":"0.994","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"PFS2; PD-L1 (TC >=1%) Analysis Set Population","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.","populationDescription":"The PD-L1 (TC \\>=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC \\>=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=1% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"296"},{"groupId":"OG002","value":"289"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"8.0","upperLimit":"12.7"},{"groupId":"OG001","value":"9.4","lowerLimit":"7.8","upperLimit":"11.4"},{"groupId":"OG002","value":"10.5","lowerLimit":"9.4","upperLimit":"11.7"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.255","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.746","ciUpperLimit":"1.080","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.534","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.787","ciUpperLimit":"1.132","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"PFS2; FAS Population","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.","populationDescription":"The FAS included all randomized participants analyzed on an ITT basis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"372"},{"groupId":"OG002","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","lowerLimit":"7.9","upperLimit":"10.6"},{"groupId":"OG001","value":"9.8","lowerLimit":"8.8","upperLimit":"11.4"},{"groupId":"OG002","value":"10.1","lowerLimit":"9.3","upperLimit":"10.8"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Durvalumab Monotherapy Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.663","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.824","ciUpperLimit":"1.131","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."},{"groupIds":["OG001","OG002"],"groupDescription":"Durvalumab + Tremelimumab Vs SoC Chemotherapy","nonInferiorityType":"SUPERIORITY","pValue":"0.103","pValueComment":"The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.746","ciUpperLimit":"1.027","estimateComment":"The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\\>=25% Vs \\<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach."}]},{"type":"SECONDARY","title":"Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months","description":"Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of \\>=10.","populationDescription":"The PD-L1 (TC \\>=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC \\>=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, \\>=25% TC expressing PD-L1 on the membrane).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"At baseline then every 4 weeks for the first 8 weeks relative to the date of randomization, then every 8 weeks until second progression/death, whichever comes first. Assessed up to 12 months.","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"162"}]}],"classes":[{"title":"EORTC QLQ-C30: Fatigue","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"107"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.83"},{"groupId":"OG001","value":"-1.1","spread":"1.92"},{"groupId":"OG002","value":"10.6","spread":"2.34"}]}]},{"title":"EORTC QLQ-C30: Appetite loss","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"107"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"2.24"},{"groupId":"OG001","value":"2.4","spread":"2.37"},{"groupId":"OG002","value":"8.0","spread":"2.83"}]}]},{"title":"EORTC QLQ-LC13: Dyspnoea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"117"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.51"},{"groupId":"OG001","value":"0.8","spread":"1.60"},{"groupId":"OG002","value":"5.6","spread":"1.90"}]}]},{"title":"EORTC QLQ-LC13: Cough","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"117"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.4","spread":"1.88"},{"groupId":"OG001","value":"-5.9","spread":"2.01"},{"groupId":"OG002","value":"-7.1","spread":"2.54"}]}]},{"title":"EORTC QLQ-LC13: Chest pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"},{"groupId":"OG002","value":"117"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.71"},{"groupId":"OG001","value":"1.6","spread":"1.80"},{"groupId":"OG002","value":"1.7","spread":"2.04"}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of Durvalumab","description":"Blood samples were collected to determine the serum concentration of durvalumab.","populationDescription":"Pharmacokinetic (PK) analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"microgram per milliliter (mcg/mL)","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, and at follow-up Month 3.","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"366"}]}],"classes":[{"title":"At Week 0: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"354"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"NA = Below lower limit of quantification (LLOQ). The LLOQ = 0.05 mcg/mL."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"NA = Below LLOQ. The LLOQ = 0.05 mcg/mL."}]}]},{"title":"At Week 0: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"349"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"484.5","spread":"210.50"},{"groupId":"OG001","value":"444.3","spread":"150.29"}]}]},{"title":"At Week 12: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"139.5","spread":"124.98"},{"groupId":"OG001","value":"140.8","spread":"146.25"}]}]},{"title":"At Week 12: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"625.3","spread":"453.8"},{"groupId":"OG001","value":"506.1","spread":"231.89"}]}]},{"title":"At Week 24: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"163.0","spread":"170.04"},{"groupId":"OG001","value":"197.0","spread":"228.79"}]}]},{"title":"At Week 24: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"123"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"598.2","spread":"344.52"},{"groupId":"OG001","value":"553.2","spread":"193.33"}]}]},{"title":"At follow-up Month 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":"132.54"},{"groupId":"OG001","value":"41.4","spread":"131.71"}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of Tremelimumab","description":"Blood samples were collected to determine the serum concentration of tremelimumab.","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mcg/mL","timeFrame":"Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3.","groups":[{"id":"OG000","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"}]}],"classes":[{"title":"At Week 0: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"358"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"NA = Below LLOQ. The LLOQ = 0.05 mcg/mL."}]}]},{"title":"At Week 0: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"359"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":"14.84"}]}]},{"title":"At Week 12: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"4.16"}]}]},{"title":"At Week 12: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"10.43"}]}]},{"title":"At follow-up Month 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab","description":"Blood samples were collected to determine the Cmax\\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mcg/mL","timeFrame":"Within 1 hour after end of infusion on infusion day at Week 12.","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"366"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"625.3","spread":"453.80"},{"groupId":"OG001","value":"506.1","spread":"231.89"}]}]}]},{"type":"SECONDARY","title":"Cmax_ss of Tremelimumab","description":"Blood samples were collected to determine the Cmax\\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mcg/mL","timeFrame":"Within 1 hour after end of infusion on infusion day at Week 12.","groups":[{"id":"OG000","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"10.43"}]}]}]},{"type":"SECONDARY","title":"Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab","description":"Blood samples were collected to determine the Ctrough\\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mcg/mL","timeFrame":"Pre-dose at Week 12.","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"366"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139.5","spread":"124.98"},{"groupId":"OG001","value":"140.8","spread":"146.25"}]}]}]},{"type":"SECONDARY","title":"Ctrough_ss of Tremelimumab","description":"Blood samples were collected to determine the Ctrough\\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mcg/mL","timeFrame":"Pre-dose at Week 12.","groups":[{"id":"OG000","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"366"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"4.16"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab","description":"Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study treatment. ADA evaluable population included participants who have non-missing durvalumab baseline ADA and at least one non-missing post-baseline durvalumab ADA result.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.","groups":[{"id":"OG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."},{"id":"OG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"223"}]}],"classes":[{"title":"ADA positive at any time","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"14"}]}]},{"title":"Treatment-emergent ADA positive","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}]},{"title":"ADA positive at baseline and post-baseline","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"ADA positive at post-baseline only","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}]},{"title":"ADA positive at baseline only","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Persistent positive","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}]},{"title":"Transient positive","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"nAb positive at any visit","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With ADA Response to Tremelimumab","description":"Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study treatment. ADA evaluable population included participants who have non-missing baseline tremelimumab ADA and at least one non-missing post-baseline tremelimumab ADA result.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.","groups":[{"id":"OG000","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"}]}],"classes":[{"title":"ADA positive at any time","categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}]},{"title":"Treatment-emergent ADA positive","categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]},{"title":"ADA positive at baseline and post-baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"ADA positive at post-baseline only","categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]},{"title":"ADA positive at baseline only","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Persistent positive","categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]},{"title":"Transient positive","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"nAb positive at any visit","categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"From first administration of study treatment up to 90 days after last dose of durvalumab and tremelimumab or 30 days after last dose of SoC or date of initiation of the first subsequent therapy, whichever occurs first, approximately 3 years. All-cause mortality, from screening up to data cut-off date (approximately 3 years 1 month).","description":"Safety analysis set included all participants who received at least 1 dose of study treatment. All-cause mortality was determined for participants in FAS.","eventGroups":[{"id":"EG000","title":"Durvalumab Monotherapy","description":"Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.","deathsNumAffected":278,"deathsNumAtRisk":374,"seriousNumAffected":131,"seriousNumAtRisk":369,"otherNumAffected":335,"otherNumAtRisk":369},{"id":"EG001","title":"Durvalumab + Tremelimumab","description":"Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.","deathsNumAffected":278,"deathsNumAtRisk":372,"seriousNumAffected":178,"seriousNumAtRisk":371,"otherNumAffected":328,"otherNumAtRisk":371},{"id":"EG002","title":"SoC Chemotherapy","description":"Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.\n\n1. Paclitaxel 200 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL.\n2. Gemcitabine 1000 or 1250 mg/m\\^2 and cisplatin 75 or 80 mg/m\\^2. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n3. Gemcitabine 1000 or 1250 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m\\^2 on Day 8 of each cycle (For squamous tumors only).\n4. Pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).\n5. Pemetrexed 500 mg/m\\^2 and carboplatin AUC 5 or 6 mg\\*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).","deathsNumAffected":297,"deathsNumAtRisk":372,"seriousNumAffected":112,"seriousNumAtRisk":352,"otherNumAffected":332,"otherNumAtRisk":352}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":18,"numAffected":14,"numAtRisk":352}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Immune thrombocytopenic purpura","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":352}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Wolff-Parkinson-White syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Autoimmune thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Secondary adrenocortical insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Secondary hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vitreous haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Autoimmune colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Colitis microscopic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":15,"numAffected":12,"numAtRisk":371},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":352}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastric perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Impaired gastric emptying","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":352}]},{"term":"Oesophageal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peptic ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Rectal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Small intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Euthanasia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":352}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acute hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bile duct obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bile duct stenosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hepatitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Infective spondylitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":20,"numAtRisk":369},{"groupId":"EG001","numEvents":28,"numAffected":21,"numAtRisk":371},{"groupId":"EG002","numEvents":22,"numAffected":19,"numAtRisk":352}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pneumonia cytomegaloviral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumonia legionella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumonia staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pneumonia streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Puncture site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Respiratory tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumocephalus","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Procedural pneumothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Subdural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Traumatic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Wound complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Wound secretion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood calcium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Fulminant type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hypophagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vitamin B1 deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Polyarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Bladder transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gastric cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rectal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Basal ganglia infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Basilar artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Facial neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypoglycaemic coma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Monoplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sensory loss","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Alcohol withdrawal syndrome","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Logorrhoea","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Organic brain syndrome","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Azotaemia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Renal infarct","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Alveolitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Hypercapnia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":352}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Diabetic foot","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pemphigoid","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Toxic skin eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood pressure inadequately controlled","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peripheral artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peripheral embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vasoconstriction","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":36,"numAtRisk":369},{"groupId":"EG001","numEvents":39,"numAffected":33,"numAtRisk":371},{"groupId":"EG002","numEvents":177,"numAffected":136,"numAtRisk":352}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Eosinophilia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Granulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypercoagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":32,"numAffected":15,"numAtRisk":352}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":352}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":123,"numAffected":65,"numAtRisk":352}]},{"term":"Neutrophilia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":352}]},{"term":"Spontaneous haematoma","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":68,"numAffected":45,"numAtRisk":352}]},{"term":"Thrombocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Acute left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":352}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cardiac flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cardiomegaly","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Diastolic dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hepatojugular reflux","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Left atrial enlargement","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Stress cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Supraventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tachyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Tricuspid valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cerumen impaction","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Deafness unilateral","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ear discomfort","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Ear pruritus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Excessive cerumen production","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Otorrhoea","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ototoxicity","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":352}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Autoimmune thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cushingoid","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Euthyroid sick syndrome","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":369},{"groupId":"EG001","numEvents":25,"numAffected":24,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":26,"numAtRisk":369},{"groupId":"EG001","numEvents":34,"numAffected":32,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Primary hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Thyroid mass","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Age-related macular degeneration","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Angle closure glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Blindness","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Blindness transient","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Conjunctival haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Conjunctivitis allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":352}]},{"term":"Episcleritis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Extraocular muscle paresis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Eye haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Eye irritation","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Eye pruritus","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Eye swelling","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Eye ulcer","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Eyelid oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Eyelid ptosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Halo vision","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":15,"numAffected":15,"numAtRisk":352}]},{"term":"Neovascular age-related macular degeneration","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ocular hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ocular hypertension","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Periorbital oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Photopsia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Polypoidal choroidal vasculopathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pterygium","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Punctate keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Uveitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Visual acuity reduced","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Vitreous floaters","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Xerophthalmia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":369},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":371},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":352}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":369},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":371},{"groupId":"EG002","numEvents":15,"numAffected":15,"numAtRisk":352}]},{"term":"Abdominal tenderness","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Abnormal faeces","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Anal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Anal incontinence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Anal pruritus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Anorectal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Aphthous ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Chilaiditi's syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Chronic gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Colitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":62,"numAtRisk":369},{"groupId":"EG001","numEvents":67,"numAffected":59,"numAtRisk":371},{"groupId":"EG002","numEvents":99,"numAffected":83,"numAtRisk":352}]},{"term":"Crohn's disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":71,"numAffected":51,"numAtRisk":369},{"groupId":"EG001","numEvents":117,"numAffected":74,"numAtRisk":371},{"groupId":"EG002","numEvents":58,"numAffected":41,"numAtRisk":352}]},{"term":"Diarrhoea haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":369},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Duodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":369},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":371},{"groupId":"EG002","numEvents":20,"numAffected":19,"numAtRisk":352}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":369},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":371},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":352}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Epigastric discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Faeces discoloured","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Faeces soft","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Frequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":352}]},{"term":"Gastritis erosive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastritis haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":352}]},{"term":"Gingival swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Haemorrhagic erosive gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypoaesthesia oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Lip swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lip ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Mouth haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Mouth swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":46,"numAtRisk":369},{"groupId":"EG001","numEvents":96,"numAffected":78,"numAtRisk":371},{"groupId":"EG002","numEvents":215,"numAffected":143,"numAtRisk":352}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oral discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Oral dysaesthesia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oral mucosal blistering","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oral mucosal erythema","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Paraesthesia oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peptic ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peritoneal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Proctalgia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Rectal tenesmus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rectal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Salivary hypersecretion","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":369},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":371},{"groupId":"EG002","numEvents":41,"numAffected":29,"numAtRisk":352}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tongue discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tongue ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":28,"numAtRisk":369},{"groupId":"EG001","numEvents":35,"numAffected":30,"numAtRisk":371},{"groupId":"EG002","numEvents":93,"numAffected":74,"numAtRisk":352}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":48,"numAtRisk":369},{"groupId":"EG001","numEvents":50,"numAffected":45,"numAtRisk":371},{"groupId":"EG002","numEvents":70,"numAffected":48,"numAtRisk":352}]},{"term":"Axillary pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Catheter site bruise","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Catheter site erosion","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Catheter site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Catheter site inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Catheter site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":369},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":371},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":352}]},{"term":"Extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Facial pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":72,"numAffected":65,"numAtRisk":369},{"groupId":"EG001","numEvents":95,"numAffected":80,"numAtRisk":371},{"groupId":"EG002","numEvents":92,"numAffected":80,"numAtRisk":352}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Feeling cold","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":352}]},{"term":"Impaired healing","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":369},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":352}]},{"term":"Infusion site extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Localised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":369},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":352}]},{"term":"Mass","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Medical device site inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Mucosal dryness","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Mucosal membrane hyperplasia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Mucous membrane disorder","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":369},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":371},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":352}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":15,"numAffected":12,"numAtRisk":352}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":30,"numAtRisk":369},{"groupId":"EG001","numEvents":32,"numAffected":29,"numAtRisk":371},{"groupId":"EG002","numEvents":33,"numAffected":28,"numAtRisk":352}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Polyp","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Puncture site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":36,"numAtRisk":369},{"groupId":"EG001","numEvents":47,"numAffected":39,"numAtRisk":371},{"groupId":"EG002","numEvents":36,"numAffected":25,"numAtRisk":352}]},{"term":"Stenosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tenderness","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vaccination site oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cholestasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Hepatic congestion","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hepatic cyst","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hepatic steatosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hepatitis toxic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hepatocellular injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Allergic oedema","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Allergy to fermented products","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Contrast media allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Contrast media reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Abdominal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Abscess oral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Aspergillus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Biliary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":369},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":371},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":352}]},{"term":"Bronchitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Carbuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Chest wall abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Clostridium colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":14,"numAffected":13,"numAtRisk":352}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cytomegalovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Epididymitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Eyelid infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Fungal pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Groin abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Herpes zoster oticus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hordeolum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Infected dermal cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":352}]},{"term":"Intervertebral discitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Lip infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":352}]},{"term":"Lung infection pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Medical device site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Mucosal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":13,"numAtRisk":369},{"groupId":"EG001","numEvents":27,"numAffected":16,"numAtRisk":371},{"groupId":"EG002","numEvents":18,"numAffected":16,"numAtRisk":352}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":352}]},{"term":"Oral fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Oral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Parainfluenzae virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pelvic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Periodontitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Perirectal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":369},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":371},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":352}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumonia necrotising","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pulpitis dental","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pyoderma","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pyuria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":352}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":352}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Severe acute respiratory syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Sialoadenitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Sweating fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tinea versicolour","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tracheobronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":18,"numAtRisk":369},{"groupId":"EG001","numEvents":19,"numAffected":12,"numAtRisk":371},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":352}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":369},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":352}]},{"term":"Vestibular neuronitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vulvovaginal mycotic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acetabulum fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Bone fissure","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Chest injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Clavicle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Foreign body in gastrointestinal tract","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Fractured sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Neck injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Palate injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Post procedural fever","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Post procedural haematuria","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Post-traumatic pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Postoperative wound complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Procedural pneumothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Radiation injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Radiation skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skeletal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Transfusion reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Traumatic intracranial haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vascular access complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Wound complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":369},{"groupId":"EG001","numEvents":24,"numAffected":22,"numAtRisk":371},{"groupId":"EG002","numEvents":21,"numAffected":18,"numAtRisk":352}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":369},{"groupId":"EG001","numEvents":23,"numAffected":18,"numAtRisk":371},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":352}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":369},{"groupId":"EG001","numEvents":24,"numAffected":22,"numAtRisk":371},{"groupId":"EG002","numEvents":16,"numAffected":14,"numAtRisk":352}]},{"term":"Blood albumin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood alkaline phosphatase decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":369},{"groupId":"EG001","numEvents":22,"numAffected":18,"numAtRisk":371},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":352}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":352}]},{"term":"Blood calcium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":371},{"groupId":"EG002","numEvents":22,"numAffected":18,"numAtRisk":352}]},{"term":"Blood electrolytes increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Blood lactate dehydrogenase abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Blood lactic acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Blood magnesium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood thyroid stimulating hormone decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Blood uric acid decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Body temperature increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Brain natriuretic peptide increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":352}]},{"term":"Carbon dioxide decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Computerised tomogram thorax abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cortisol decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Creatinine renal clearance decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Ejection fraction decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Fibrin D dimer increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":13,"numAtRisk":369},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":371},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":352}]},{"term":"Haematocrit decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Haemoglobin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Intraocular pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":369},{"groupId":"EG001","numEvents":22,"numAffected":15,"numAtRisk":371},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":352}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Liver function test decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Liver function test increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Lymph node palpable","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":352}]},{"term":"Monocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":52,"numAffected":23,"numAtRisk":352}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":34,"numAffected":20,"numAtRisk":352}]},{"term":"Platelet count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Protein total decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Protein urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Prothrombin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Red blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Red blood cells urine","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Staphylococcus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Thyroxine free decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Tri-iodothyronine decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tri-iodothyronine free decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tri-iodothyronine free increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Troponin I increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Urine ketone body present","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Urine output decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Urine sodium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vitamin D decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":39,"numAtRisk":369},{"groupId":"EG001","numEvents":45,"numAffected":43,"numAtRisk":371},{"groupId":"EG002","numEvents":21,"numAffected":18,"numAtRisk":352}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":33,"numAffected":19,"numAtRisk":352}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":352}]},{"term":"Acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Appetite disorder","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":73,"numAtRisk":369},{"groupId":"EG001","numEvents":101,"numAffected":89,"numAtRisk":371},{"groupId":"EG002","numEvents":88,"numAffected":78,"numAtRisk":352}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":371},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":352}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dyslipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Fluid imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Folate deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Glucose tolerance impaired","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperamylasaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypercreatininaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":369},{"groupId":"EG001","numEvents":24,"numAffected":16,"numAtRisk":371},{"groupId":"EG002","numEvents":14,"numAffected":10,"numAtRisk":352}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":352}]},{"term":"Hyperlipasaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypermagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hyperphagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":369},{"groupId":"EG001","numEvents":13,"numAffected":10,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":352}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":369},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":371},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":352}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":12,"numAtRisk":369},{"groupId":"EG001","numEvents":26,"numAffected":21,"numAtRisk":371},{"groupId":"EG002","numEvents":17,"numAffected":16,"numAtRisk":352}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":19,"numAffected":19,"numAtRisk":352}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":369},{"groupId":"EG001","numEvents":20,"numAffected":17,"numAtRisk":371},{"groupId":"EG002","numEvents":14,"numAffected":12,"numAtRisk":352}]},{"term":"Hypophagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":352}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Iron deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Protein deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Vitamin D deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":34,"numAtRisk":369},{"groupId":"EG001","numEvents":27,"numAffected":24,"numAtRisk":371},{"groupId":"EG002","numEvents":15,"numAffected":12,"numAtRisk":352}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Autoimmune arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Back disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":39,"numAtRisk":369},{"groupId":"EG001","numEvents":45,"numAffected":38,"numAtRisk":371},{"groupId":"EG002","numEvents":34,"numAffected":32,"numAtRisk":352}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":352}]},{"term":"Bursitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cervical spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Clubbing","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Costochondritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Fistula inflammation","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":352}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Hypertrophic osteoarthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Joint effusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Joint stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Limb discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Mastication disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Metatarsalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Muscle contracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":371},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":352}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":369},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":371},{"groupId":"EG002","numEvents":14,"numAffected":13,"numAtRisk":352}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":31,"numAtRisk":369},{"groupId":"EG001","numEvents":21,"numAffected":17,"numAtRisk":371},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":352}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":369},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":371},{"groupId":"EG002","numEvents":30,"numAffected":16,"numAtRisk":352}]},{"term":"Myalgia intercostal","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Myopathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Myosclerosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":369},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":371},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":352}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Osteochondrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":19,"numAtRisk":369},{"groupId":"EG001","numEvents":25,"numAffected":23,"numAtRisk":371},{"groupId":"EG002","numEvents":15,"numAffected":14,"numAtRisk":352}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Polyarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"SAPHO syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Scleroderma","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sjogren's syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Soft tissue swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tendon calcification","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tendon discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Trismus","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Colon adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gastrointestinal tract adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Infected neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Melanocytic naevus","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Meningioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oncologic complication","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pituitary tumour benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Seborrhoeic keratosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin papilloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Thyroid adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":352}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tumour thrombosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ageusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Auditory nerve disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Carpal tunnel syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":369},{"groupId":"EG001","numEvents":35,"numAffected":25,"numAtRisk":371},{"groupId":"EG002","numEvents":21,"numAffected":20,"numAtRisk":352}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Drooling","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Dysaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":369},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":19,"numAffected":17,"numAtRisk":352}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Head discomfort","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":23,"numAtRisk":369},{"groupId":"EG001","numEvents":36,"numAffected":25,"numAtRisk":371},{"groupId":"EG002","numEvents":29,"numAffected":22,"numAtRisk":352}]},{"term":"Hemianopia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Horner's syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":352}]},{"term":"Hypokinesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Intercostal neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Intracranial aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Ischaemic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neurological decompensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":16,"numAffected":14,"numAtRisk":352}]},{"term":"Nystagmus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":369},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":15,"numAffected":14,"numAtRisk":352}]},{"term":"Parosmia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":352}]},{"term":"Peroneal nerve palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":352}]},{"term":"Poor quality sleep","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Post herpetic neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Radicular syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Restless legs syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Seizure like phenomena","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sensory loss","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sinus headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Speech disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Stupor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Toxic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Trigeminal neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vertebral artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Thrombosis in device","organSystem":"Product Issues","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Adjustment disorder with depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Aggression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":369},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":371},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":352}]},{"term":"Apathy","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Aversion","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":352}]},{"term":"Disorganised speech","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Euphoric mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hallucination, auditory","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":27,"numAtRisk":369},{"groupId":"EG001","numEvents":42,"numAffected":37,"numAtRisk":371},{"groupId":"EG002","numEvents":23,"numAffected":22,"numAtRisk":352}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Libido decreased","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Listless","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Mood altered","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Mood swings","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nervousness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Panic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Substance-induced psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Azotaemia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Bladder dilatation","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bladder pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Chromaturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Glycosuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Leukocyturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Micturition urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Nephropathy toxic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Nocturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Polyuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Prerenal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pyelocaliectasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":352}]},{"term":"Renal pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Renal tubular disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Stress urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Ureteric haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Urethral dilatation","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Breast enlargement","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dyspareunia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Genital cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Genital rash","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Gynaecomastia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nipple disorder","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Penile haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Penile pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Plasma cell balanitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Prostatism","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Scrotal cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Scrotal erythema","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Allergic cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bronchial hyperreactivity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bronchial secretion retention","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Catarrh","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":369},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":40,"numAtRisk":369},{"groupId":"EG001","numEvents":41,"numAffected":38,"numAtRisk":371},{"groupId":"EG002","numEvents":33,"numAffected":26,"numAtRisk":352}]},{"term":"Diaphragmalgia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Dysaesthesia pharynx","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":34,"numAtRisk":369},{"groupId":"EG001","numEvents":35,"numAffected":32,"numAtRisk":371},{"groupId":"EG002","numEvents":35,"numAffected":31,"numAtRisk":352}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":369},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":352}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":369},{"groupId":"EG001","numEvents":28,"numAffected":18,"numAtRisk":371},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":352}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":21,"numAffected":18,"numAtRisk":352}]},{"term":"Hyperventilation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Laryngeal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Nasal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nasal septum deviation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nasal ulcer","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Organising pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":371},{"groupId":"EG002","numEvents":11,"numAffected":11,"numAtRisk":352}]},{"term":"Orthopnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Painful respiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pharyngeal oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":20,"numAtRisk":369},{"groupId":"EG001","numEvents":26,"numAffected":23,"numAtRisk":371},{"groupId":"EG002","numEvents":18,"numAffected":18,"numAtRisk":352}]},{"term":"Pulmonary artery thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pulmonary mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pulmonary pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Respiratory acidosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Restrictive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":369},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":11,"numAffected":11,"numAtRisk":352}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Sputum increased","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Sputum retention","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Tachypnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Throat irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Throat tightness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Upper-airway cough syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Actinic keratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":371},{"groupId":"EG002","numEvents":42,"numAffected":42,"numAtRisk":352}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Blister","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Butterfly rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Chloasma","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Cold sweat","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":352}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Dermal cyst","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":369},{"groupId":"EG001","numEvents":22,"numAffected":21,"numAtRisk":371},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":352}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Eczema asteatotic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Exfoliative rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Haemorrhage subcutaneous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hair growth abnormal","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Hyperkeratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Intertrigo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Koilonychia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Lichenoid keratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Macule","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Milia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Miliaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Nail dystrophy","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Nodular vasculitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Onycholysis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Onychomadesis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Pain of skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Papule","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Penile ulceration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Petechiae","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Photosensitivity reaction","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pigmentation disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Post inflammatory pigmentation change","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":42,"numAtRisk":369},{"groupId":"EG001","numEvents":81,"numAffected":67,"numAtRisk":371},{"groupId":"EG002","numEvents":21,"numAffected":17,"numAtRisk":352}]},{"term":"Pruritus generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Psoriasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":39,"numAtRisk":369},{"groupId":"EG001","numEvents":66,"numAffected":57,"numAtRisk":371},{"groupId":"EG002","numEvents":44,"numAffected":40,"numAtRisk":352}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rash generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":369},{"groupId":"EG001","numEvents":22,"numAffected":20,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Rash vesicular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Scab","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Seborrhoeic dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":6,"numAffected":2,"numAtRisk":352}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Skin hypopigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin induration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin irritation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin mass","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin necrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin swelling","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Swelling face","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Toxic skin eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":369},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Vitiligo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Angiopathy","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Arterial thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Brachiocephalic vein occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Capillary leak syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Circulatory collapse","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":371},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":352}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":352}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":352}]},{"term":"Hyperaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":369},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":371},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":352}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":369},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":371},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":352}]},{"term":"Ischaemic limb pain","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Jugular vein distension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Microangiopathy","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Pallor","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":352}]},{"term":"Superior vena cava occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":352}]},{"term":"Thrombophlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":352}]},{"term":"Vasculitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Vasoconstriction","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]},{"term":"Vasodilatation","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Vein disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":352}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":369},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":371},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":352}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Global Clinical Lead","organization":"AstraZeneca","email":"ClinicalTrialTransparency@astrazeneca.com","phone":"+1 302 885 1180"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-01-09","uploadDate":"2024-07-30T04:56","filename":"Prot_015.pdf","size":2195088},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-06-20","uploadDate":"2019-10-04T03:19","filename":"SAP_000.pdf","size":13601116}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"},{"id":"C053518","term":"CP protocol"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"},{"id":"D000068437","term":"Pemetrexed"},{"id":"C520704","term":"tremelimumab"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}